職位描述
崗位職責(zé)：
1、了解泰凌發(fā)展歷史、企業(yè)核心價(jià)值觀及組織結(jié)構(gòu)；
2、學(xué)習(xí)業(yè)務(wù)流程，熟悉產(chǎn)品推廣模式，掌握相關(guān)專業(yè)知識(shí)；
3、接受相關(guān)培訓(xùn)，跟隨區(qū)域同事學(xué)習(xí)合規(guī)的工作方式以及了解學(xué)術(shù)推廣活動(dòng)的組織及收集市場(chǎng)信息的反饋的標(biāo)準(zhǔn)流程；
4、熟悉醫(yī)學(xué)信息溝通專員的基本工作內(nèi)容，學(xué)習(xí)工作的方式方法；
5、在實(shí)習(xí)各個(gè)階段隨時(shí)接受學(xué)習(xí)成果的考核。
任職資格：
1、2019級(jí)在校生，專科及以上學(xué)歷，專業(yè)不限；臨床醫(yī)學(xué)、藥學(xué)及醫(yī)藥/生物相關(guān)專業(yè)優(yōu)先；
2、良好的溝通能力和較高的人際敏感度，良好的再學(xué)習(xí)能力和主動(dòng)學(xué)習(xí)意愿；
3、樂觀積極，有一定的壓力承受力以及良好的團(tuán)隊(duì)合作精神；
4、能使用Office辦公軟件。
企業(yè)簡(jiǎn)介
企業(yè)介紹
ENTERPRISE PROFILE
泰凌總部位于香港，在上海、北京、廣州設(shè)有投資、營(yíng)銷管理、研發(fā)及醫(yī)學(xué)事務(wù)中心，在蘇州、泰州、長(zhǎng)沙及瑞士建有生產(chǎn)基地。目前，集團(tuán)擁有20余家子公司。
NT PHARMA'S HEADQUARTER IS BASED IN HONG KONG WHICH INCLUDES INTERNATIONAL BUSINESS AND INVESTMENT GROUP. MARKETING MANAGEMENT, RESEARCH AND DEVELOPMENT AND MEDICAL BUSINESS CENTRES ARE BASED IN SHANGHAI, BEIJING,AND GUANGZHOU. OUR PRODUCTION AND MANUFACTURING FACTORIES ARE BASED IN SUZHOU, TAIZHOU, CHANGSHA AND SWITZERLAND. CURRENTLY NT PHARMA GROUP HAS MORE THAN 20 SUBSIDIARIES.
集團(tuán)的核心產(chǎn)品覆蓋了腫瘤及血液系統(tǒng)疾病、骨代謝疾病、消化系統(tǒng)疾病、中樞神經(jīng)系統(tǒng)疾病、呼吸系統(tǒng)疾病等多個(gè)治療領(lǐng)域，主要有：國(guó)際著名骨科品牌“密蓋息”(鮭魚降鈣素)，國(guó)家1.1類腫瘤新藥“喜滴克”（尿多酸肽注射液），國(guó)家肝病新藥“松梔丸”，品牌仿制藥“舒思”（富馬酸喹硫平片）等20余種產(chǎn)品。這些藥品覆蓋了中國(guó)除西藏、臺(tái)灣以外的廣大地區(qū)，近20,000家醫(yī)療機(jī)構(gòu)，并受到中國(guó)醫(yī)療機(jī)構(gòu)的廣泛認(rèn)同。
WE FOCUS ON DEVELOPMENT OF CORE PRODUCTS OF OUR BRAND COVERING TUMOUR AND BLOOD SYSTEM DISEASES, DIGESTIVE SYSTEM DISEASES, CENTRAL NERVOUS DISEASES, DISEASES OF RESPIRATORY SYSTEM AND OTHER THERAPEUTIC FIELDS. OUR MAIN PRODUCTS INCLUDES: WORLD RENOWNED ORTHOPAEDIC BRAND "MIACALCIC" (SALMON CALCITONIN), NATIONAL 1.1-CLASS NEW TUMOR DRUG "XIDIKE" (UROACITIDES INJECTION), NATIONAL HEPATIC NEW DRUG "SONGZHI PILL", BRAND GENERIC DRUG "SHUSI" (FUMARIC ACID QUETIAPIEN TABLETS) AND 20+ OTHER PRODUCTS. OUR PRODUCTS HAVE BEEN DISTRIBUTED BY MORE THAN 20,000 MEDICAL INSTITUTIONS ALL OVER CHINA EXCEPT FOR TIBET AND TAIWAN AND IS WIDELY RECOGNIZED BY CHINESE MEDICAL INSTITUTIONS.
泰凌自創(chuàng)建以來(lái)，一直致力于成為面向世界的國(guó)際化醫(yī)藥企業(yè)，“密蓋息”遠(yuǎn)銷世界20余個(gè)國(guó)家地區(qū)，“舒思”遠(yuǎn)銷歐洲市場(chǎng)。同時(shí)，與諸多世界領(lǐng)先跨國(guó)醫(yī)藥企業(yè)建立了長(zhǎng)期戰(zhàn)略合作關(guān)系，包括葛蘭素史克(GSK)、輝瑞(Pfizer)、羅氏(Roche)、諾華(Novartis)、貝朗(B|BRAUN)等。
SINCE OUR ESTABLISHMENT, NT PHARMA HAS BEEN DEVOTED TO BECOME A WORLD-ORIENTED INTERNATIONALIZED PHARMACEUTICAL ENTERPRISE. "MIACALCIC" HAS BEEN USED IN MORE THAN 20 COUNTRIES AND REGIONS. "SHUSI" HAS ITS STRONG MARKETS IN EUROPE MARKET MEANWHILE NT PHARMA HAS MANY LONG-TERM STRATEGIC COOPERATION RELATION WITH WORLD LEADING MULTINATIONAL PHARMACEUTICAL ENTERPRISES INCLUDING GLAXOSMITHKLINE (GSK), PFIZER, ROCHE, NOVARTIS AND BIBRAUN.
[展開全文]
[收縮全文]
